Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Opdivo CDx Approved for Expanded Use in Europe

NEW YORK (GenomeWeb) – Agilent Technologies announced today that it has been granted expanded use in Europe for its Dako PD-L1 IHC 28-8 pharmDx test, a companion diagnostic for Bristol-Myers Squibb's cancer drug Opdivo (nivolumab).

According to Agilent, the test is now approved for identifying patients with squamous cell carcinoma of the head and neck who are likely to benefit from Opdivo therapy. The test is already approved in Europe for tumor cell PD-L1 expression for non-squamous non-small-cell lung cancer (ns-NSCLC) and melanoma.

It is also approved in the US as a complementary diagnostic for Opdivo for ns-NSCLC and for assessing the magnitude of benefit melanoma patients might derive from the drug. 

"We recently saw the first approval for the PD-L1 IHC 28-8 pharmDx test in head and neck cancer in Japan, and are now pleased that the CE marked indication has been extended to Europe," Jacob Thaysen, president of Agilent's diagnostics and genomics group, said in a statement. "Head and neck cancer has few treatment options, and tumor PD-L1 testing can identify patients with this devastating disease who are most likely to benefit from Opdivo therapy."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.